SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-028982
Filing Date
2023-06-20
Accepted
2023-06-20 17:17:28
Documents
12
Period of Report
2023-06-14
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K janx-20230614.htm   iXBRL 8-K 80516
  Complete submission text file 0000950170-23-028982.txt   208002

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20230614_pre.xml EX-101.PRE 11925
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20230614.xsd EX-101.SCH 2461
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20230614_lab.xml EX-101.LAB 14743
6 EXTRACTED XBRL INSTANCE DOCUMENT janx-20230614_htm.xml XML 5113
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 231026365
SIC: 2834 Pharmaceutical Preparations